Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
AssigneeOPKO CuRNA, LLC
InventorsJoseph Collard, Olga Khorkova Sherman
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
Claims39
A method of a function of and/or the expression of a Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1028 of SEQ ID NO:
- 5 or nucleotides 1 to 429 of SEQ ID NO:
- 6, or nucleotides 1 to 156 of SEQ ID NO:
- 7 or nucleotides 1 to 593 of SEQ ID NO:8, 1 to 373 of SEQ ID NO:
- 9, 1 to 1713 of SEQ ID NO:
- 10, 1 to 660 of SEQ ID NO:11, 1 to 589 of SEQ ID NO:
- 12, 1 to 428 of SEQ ID NO:
- 13 and 1 to 4041 of SEQ ID NO:
- 14;
- thereby modulating a function of and/or the expression of the Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro.
A method of modulating a function of and/or the expression of a Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Sirtuin (SIRT) polynucleotide;
- thereby modulating a function of and/or the expression of the Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro.
A method of modulating a function of and/or the expression of a Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Sirtuin (SIRT) polynucleotide;
- thereby modulating a function of and/or the expression of the Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro.
A method of modulating a function of and/or the expression of a Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide that targets a region of a natural antisense oligonucleotide of the Sirtuin (SIRT) polynucleotide;
- thereby modulating a function of and/or the expression of the Sirtuin (SIRT) polynucleotide in patient cells or tissues in vivo or in vitro.
A method of modulating a function of and/or the expression of a Sirtuin (SIRT) in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 5 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a Sirtuin (SIRT) polynucleotide, wherein said at least one siRNA oligonucleotide has at least 50% sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense nucleic acid molecule of the Sirtuin (SIRT) polynucleotide;
- and, modulating a function of and/or the expression of a Sirtuin (SIRT) in mammalian cells or tissues in vivo or in vitro.
A method of modulating a function of and/or the expression of a Sirtuin (SIRT) in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide of about 5 to 30 nucleotides in length specific for noncoding and/or coding sequences of a sense and/or natural antisense strand of a Sirtuin (SIRT) polynucleotide wherein said at least one antisense oligonucleotide has at least 50% sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS:
- 1 to 14;
- and, modulating the function and/or expression of the Sirtuin (SIRT) in mammalian cells or tissues in vivo or in vitro.
A synthetic, modified oligonucleotide comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
- at least one modified internucleotide linkage;
- at least one modified nucleotide, and combinations thereof;
- wherein said oligonucleotide is an antisense compound which hybridizes to and modulates the function and/or expression of a Sirtuin (SIRT) in vivo or in vitro as compared to a normal control.
A composition comprising one or more oligonucleotides specific for one or more Sirtuin (SIRT) polynucleotides, said polynucleotides comprising antisense sequences, complementary sequences, alleles, homologs, isoforms, variants, derivatives, mutants, fragments, or combinations thereof.
A method of preventing or treating a disease associated with at least one Sirtuin (SIRT) polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide that binds to a natural antisense sequence of said at least one Sirtuin (SIRT) polynucleotide and modulates expression of said at least one Sirtuin (SIRT) polynucleotide;
- thereby preventing or treating the disease associated with the at least one Sirtuin (SIRT) polynucleotide and/or at least one encoded product thereof.
A method of preventing or treating a skin condition associated with at least one Sirtuin (SIRT) polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient having a skin condition or at risk of developing a skin condition a therapeutically effective dose of at least one antisense oligonucleotide that binds to a natural antisense sequence of said at least one Sirtuin (SIRT) polynucleotide and modulates expression of said at least one Sirtuin (SIRT) polynucleotide;
- thereby preventing or treating the disease skin condition associated with the at least one Sirtuin (SIRT) polynucleotide and/or at least one encoded product thereof.
The method of claim 38, wherein the skin condition is caused by caused by inflammation, light damage or aging.
The method of claim 39, wherein the skin condition is the development of wrinkles, contact dermatitis, ample dermatitis, actinic keratosis, keratinization disorders, an epidermolysis bullosa disease, exfoliative dermatitis, seborrheic dermatitis, an erythema, discoid lupus erythematosus, dermatomyositis, skin cancer, or an effect of natural aging.
Dependencies are inferred from the claim text.